Email us: firstname.lastname@example.org
In April of 2013, California will be the 5th state mandating that a physician notify a patient if they have dense breast tissue. Eleven more states, and now the federal government, have similar laws in process today. Thanks to the efforts of an advocacy group of breast cancer survivors, D.E.N.S.E (Density Education National Survivors Network), women will now be informed that their condition interferes with the effectiveness of mammograms to identify tumors in their breasts. With an early diagnosis (Stage 1), survival rate is exceptional at 95%, however the later the diagnosis the lower the survival rate, with only 35% surviving if diagnosed in Stage 3. With the limitation of diagnostic tools such as mammography and ultrasound to detect cancer in dense breasts, another medium of screening must evolve.
FWS is taking steps to ensure early detection of metabolic cellular changes leading to cancer, no matter what age or tissue density. With over $12M in research and development, 650 human trials, and now over 5 years of advanced algorithmic research at the prestigious Nanyang Technical University in Singapore, we are now finalizing our proof of concept with a targeted study to ensure reproducible results can be expected.
First Warning’s non-radiative approach allows a patient to simply wear a sport bra with specialized sensors designed to assess early metabolic circadian patterns at a cellular level. Automated quantifiable results are then delivered to the physician to support the clinical decision process. The FWS is not intended to diagnose disease, but to simply become an accurate, accessible, and affordable early warning system for users and practitioners. FWS’s target is to eventually compare our findings with key genomic and proteomic markers which signify early abnormal cellular change, and early trials indicate this can be achieved.
First Warning Systems, Inc. 1325 Airmotive Way, Ste 175-L Reno, NV 89502